key: cord-0890887-8vts1isl
authors: Dhall, Anjali; Patiyal, Sumeet; Raghava, Gajendra P. S.
title: HLAncPred: A method for predicting promiscuous non-classical HLA binding sites
date: 2021-12-06
journal: bioRxiv
DOI: 10.1101/2021.12.04.471207
sha: 85ee1edc6573544fbf157cd9d876d65a4253e4b9
doc_id: 890887
cord_uid: 8vts1isl

In the last two decades, ample of methods have been developed to predict the classical HLA binders in an antigen. In contrast, limited attempts have been made to develop methods for predicting binders for non-classical HLA; due to the scarcity of sufficient experimental data and lack of community interest. Of Note, non-classical HLA plays a crucial immunomodulatory role and regulates various immune responses. Recent studies revealed that non-classical HLA (HLA-E & HLA-G) based immunotherapies have many advantages over classical HLA based-immunotherapy, particularly against COVID-19. In order to facilitate the scientific community, we have developed an artificial intelligence-based method for predicting binders of non-classical HLA alleles (HLA-G and HLA-E). All the models were trained and tested on experimentally validated data obtained from the recent release of IEDB. The machine learning based-models achieved more than 0.98 AUC for HLA-G alleles on validation or independent dataset. Similarly, our models achieved the highest AUC of 0.96 and 0.88 on the validation dataset for HLA-E*01:01, HLA-E*01:03, respectively. We have summarized the models developed in the past for non-classical HLA binders and compared with the models developed in this study. Moreover, we have also predicted the non-classical HLA binders in the spike protein of different variants of virus causing COVID-19 including omicron (B.1.1.529) to facilitate the community. One of the major challenges in the field of immunotherapy is to identify the promiscuous binders or antigenic regions that can bind to a large number of HLA alleles. In order to predict the promiscuous binders for the non-classical HLA alleles, we developed a web server HLAncPred (https://webs.iiitd.edu.in/raghava/hlancpred), and a standalone package. Key Points Non-classical HLAs play immunomodulatory roles in the immune system. HLA-E restricted T-cell therapy may reduce COVID-19 associated cytokine storm. In silico models developed for predicting binders for HLA-G and HLA-E. Identification of non-classical HLA binders in strains of coronavirus A webserver for predicting promiscuous binders for non-classical HLA alleles Author’s Biography Anjali Dhall is currently working as Ph.D. in Bioinformatics from Department of Computational Biology, Indraprastha Institute of Information Technology, New Delhi, India. Sumeet Patiyal is currently working as Ph.D. in Bioinformatics from Department of Computational Biology, Indraprastha Institute of Information Technology, New Delhi, India. Gajendra P. S. Raghava is currently working as Professor and Head of Department of Computational Biology, Indraprastha Institute of Information Technology, New Delhi, India.

There are two well-known mechanisms for antigen representation by HLA-E alleles, which 104 decide the cells' fate. HLA-E binds to the peptide fragments descended from the signal 105 sequence of other class Ia HLA-alleles, and this representation leads to the inhibition of NK 106 cell functions by interacting with the NKG2A/CD94 receptors on NK cells. However, some 107 studies revealed that the peptides from the virus (such as SARS-CoV-2, Epstein Barr Virus, 108

Cytomegalovirus, and Hepatitis C Virus) are presented by HLA-E on the cell surface and 109 recognised by virus specific immune cells which further activate the immune responses [32-110 39] . Moreover, CD8+ T-cell interaction with HLA-E leads to the production of anti-111 inflammatory cytokines (TGF-b, IL-4, IL-10), which is responsible for the down-regulation 112 of pro-inflammatory cytokines production and, therefore, inhibiting the cytokine storm which 113 plays a crucial role in the COVID-19 pathogenesis. The inhibition of cytokine storm also 114 lowers the degree of tissue damage [40] . Several studies reveals that HLA-E inhibits NK 115 mediated lysis, cytotoxicity, cytokine secretion, and tumor proliferation [39, [41] [42] [43] , as 116 represented in Figure 1 . These findings suggest that HLA-G and HLA-E could be essential 117 immune checkpoint molecules for designing novel immunotherapies or subunit vaccines 118 against a wide range of diseases. 119 Thus, there is a need to develop methods for predicting non-classical HLA binders. Though 123 numerous computational methods have been developed in the past for predicting HLA binder 124 but majorly focused on classical HLA [44] [45] [46] [47] [48] [49] [50] . Only a few tools incorporate models for 125 predicting binders for non-classical HLA alleles. Best of our knowledge no tool has been 126 explicitly developed for predicting non-classical HLA binders. This study is dedicated for 127 non-classical HLA, where a systematic attempt has been made to develop models for 128 predicting non-classical HLA binders. We obtained and examined all experimentally 129 validated non-classical HLA binders from IEDB. Based on availability of sufficient data in 130 IEDB, we developed models for predicting binders for following non-classical alleles HLA-131 G*01:01, HLA-G*01:03, HLA-G*01:04, HLA-E*01:01 and HLA-E*01:03. We have used 132 various machine learning models for the better prediction of non-classical HLA binders. 133 134

Dataset collection and pre-processing 136

We have collected the experimentally validated non-classical Class-I HLA-binding peptides, 137

i.e., 1135 HLA-E and 5151 HLA-G, from the immune epitope database (IEDB), accessed on 138 26 October 2021. Further, we removed redundant peptides with lengths (greater than 15 or 139 less than 8) from the dataset. After that, we obtained 142 and 723 unique peptides for HLA-140 E*01:01 and -E*01:03 alleles, respectively. Similarly, we get 2633, 751, and 812 unique 141 binding peptides for HLA-G*01:01, -G*01:03, and -G*01:04 alleles, respectively. One of the 142 major challenge in this type of study is the availability of negative dataset. Due to limited 143 number of negative peptides in IEDB, we randomly generate the HLA-G, HLA-E non-144 In the current study, we performed amino-acid positional analysis using TSL tool [52] , 165 utilizing fixed-length peptide sequences used in previous studies [53] [54] [55] . In our dataset, the 166 minimum length of peptides is eight, and hence, we create fixed-length peptides having 167 sixteen residues. In order to create a fixed-length vector, we picked eight residues from N-168 terminal and eight residues from C-terminal; further, we merged the two sequences and got 169 the final sixteen residue peptides for each positive and negative dataset. In this study, we used Pfeature [56] to calculate the binary profile for each peptide belong to 174 binder and non-binder class. In order to calculate the binary profiles the length of the variable 175 should be fixed, but the length of the peptides were varying from 8 to 15. Thus, to generate 176 the fixed length vector, we extracted same number of residues from the N-and C-terminal of 177 the peptides. Since, the minimum length of the peptides was 8, hence we chose to select the 178 eight residues from each end and designed different patterns to calculate features. First, eight 179 residues were selected from N-terminal, and designated as N 8 patterns; similarly, eight 180 residues were chosen from C-terminal and referred as C 8 residues. Another patterns of length 181 16 were generated by joining the eight residues from N-and C-terminal and referred as N 8 C 8 . 182

For the afore-mentioned patterns, each amino acid is represented by the vector of length 20, 183

where each element represents the presence/absence of that residues, where presence was 184 designated as "1" and absence was presented by "0". For instance, residue "A" was 185 represented as by vector 1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0; hence, total length of vector 186 generated for patterns N 8 and C 8 was 160 (20*8) and for N 8 C 8 its 320 (20*16). 187

Likewise, patterns of peptides with maximum length (i.e., 15 amino acids) were generated 188 and termed as AA 15 and binary profile was calculated. In this case, residues "X" were added 189 in the peptides having length less than 15. For example, 7 "X" were added in the peptide 190 having length equal to 8, in order to make its length 15, such as peptide "VYIKHPVS" 191 became "VYIKHPVSXXXXXXX". In this scenario, each amino acid is represented by the 192 vector size of 21, where last element exhibited presence/absence of "X". Residue "V" is 193 represented by vector 0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0 and "X" is presented as 194 0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1. We have applied a 5-fold cross-validation technique to evade the curse of biasness and 207 overfitting in the generated models. It is one of the most crucial steps to evaluate the 208 prediction model. In this approach, the entire dataset is partitioned into five parts, out of 209 which four are used in training, and the resulted model is tested on the left one. The exact 210 process is reproduced five times so that each part gets the opportunity to act as the testing 211 dataset. Ultimately, the final performance is represented as the average of the performance of 212 the five models that resulted from the five iterations. 213 214 Evaluation parameters 215 216 Several parameters can be employed to assess the prediction models, which can be broadly 217 classified into two categories termed as threshold-dependent and -independent parameters. In 218 this study, we have determined sensitivity, specificity, accuracy, F1-score, and Matthews 219 correlation coefficient (MCC) as the threshold-dependent parameters, whereas Area Under 220

Receiver Operating Characteristics (AUC) curve is calculated as the threshold-independent 221 parameter. Sensitivity (equation 1) is the measure of the ability of the model to correctly 222 predict the binders, whereas specificity (equation 2) accounts for the percentage of correctly 223 predicted non-binders. Accuracy (equation 3) exhibits the percentage of the correctly 224 predicted binders and non-binders, F1-score (equation 4) captures the balance between 225 precision and recall, and MCC (equation 5) explains the relation between the predicted and 226 observed values. AUC is a plot between the sensitivity and 1-specificity, which captures the 227 ability of the model to distinguish between the classes. 228

Where, T P , T N , F P and F N stands for true positive, true negative, false positive and false 230 negative, respectively. 231 232

The average amino acid composition of HLA-G and HLA-E binding and non-binding 236 peptides are represented in Figure 2 . As shown in the graphs, the compositional difference in 237 positive and negative dataset is clearly visible. HLA-G*01:01, -G*01:03, -G*01:04 alleles 238 binders (i.e., positive peptides) have higher composition of residues such as Isoleucine (I), 239

Lysine (K), Leucine (L) and Proline (P) as compared to non-binding peptides as depicted in 240 In order to analyze and study the preference or relative abundance of specific amino acid 251 residues at a particular position in the non-classical HLA binder/non-binder sequences; we generate TSL plots (Figure 3 ). Of note, we generated the fixed length peptide having sixteen 253 residues, where the first eight residues represent the N-terminal and last eight residues are C-254 terminal of each peptide sequence. From the TSL analysis we found that amino acid 'L' is 255 predominately preferred at 2 nd , 7 th , 8 th , 9 th , 10 th , 11 th , and 16 th position in HLA-G*01:01 256 binding peptides ( Figure 3A ); at position 2 nd , 8 th , 9 th , 11 th , and 16 th in HLA-G*01:03 binders 257 ( Figure 3B ); and at position 2 nd , 7 th , 8 th , 9 th , 11 th , and 16 th in HLA-G*01:04 binding peptides 258 ( Figure 3B ). Whereas, 'I' is most preferred at 2 nd , 3 rd , 7 th , 11 th , 15 th , and 16 th position in all 259 HLA-G alleles binders as shown in Figure 3 (A, B, C). On the other side, 'P' residue is 260 preferentially located at 3 rd , 4 th , 7 th , 11 th , 14 th , and 15 th positions in HLA-E*01:01 binders and 261 4 th , 6 th , 7 th , 12 th , and 14 th positions are predominantly occurred in HLA-E*01:03 binders. 262

While 'L' amino acid is preferred at position 2 nd , 8 th , 9 th , 10 th in HLA-E*01:01, however 2 nd , 263 6 th , 9 th , 12 th , and 16 th positions are mainly inhabited in HLA-E*01:03 binders. 264 We compute performance of each allele dataset using various machine learning classifiers 280 with four feature-sets as depicted in Supplementary Table S1 . Further, we observed that AA 15 281 binary profiles based-models outperform other feature-sets with balanced sensitivity and 282 specificity. As shown in Table 2 , HLA-G*01:01 dataset achieved maximum AUC of 0.99 283 and accuracy >95% on both training and validation dataset using SVC classifier (Table 2) . 284 ET based models also shows similar results on training and validation dataset with AUC of 285 0.99 and accuracy >95% ( Table 3 . Similarly, models based on ET also perform equivalent with very less 312 difference in sensitivity and specificity ( 

Comparison with existing methods 322 323 It is very important to compare this new method with the existing methods in order to 324 understand the advantage/disadvantages. To validate our method, we compare the 325 performance of our models with the existing methods (MHCflurry 2.0 and NetMHCpan 4.1). 326

We have trained our models on the previous used dataset, which is provided by MHCflurry 327 2.0 for HLA-G alleles only, because in case of HLA-E the number of peptides used in 328 previous methods is very less. Further, we validate the performance of all the methods on the 329 updated IEDB positive binders of (HLA-G*01:01, -G*01:03, and -G*01:04) alleles. As 330 shown in the results, HLA nc Pred outperform other methods for the prediction of HLA-G 331 binding peptides with balanced sensitivity, specificity, and maximum accuracy (Table 4) . 332

Whereas, MHCflurry 2.0 also performs quite well on the prediction of binder/non-binding 333 peptides of HLA-G*01:01 dataset but perform poor on other datasets. Similarly, we observed 334 NetMHCpan 4.1 perform poorly on the validation dataset. 335 336 

In the current study, for assisting the scientific community in the prediction and scanning of 345 non-classical HLA-binder and non-binder peptides, we have developed a web-based service 346 "HLA nc Pred" (https://webs.iiitd.edu.in/raghava/hlancpred/). In this web-server we have used 347 our best models for the better prediction of HLA-binders. The detail description of 348 HLA nc Pred modules are given below. 349 The 'HLA nc Pred' web-server is compatible with a number of devices (iPhone, iPad, laptops, 373 android mobile phones, etc.) and was build using HTML, PHP and JAVA scripts. 374

Several studies have shown that HLA-allele binding sites significantly influence the severity 376 of COVID-19 disease [8, 27, 40, 59] . Recently, World Health Organisation (WHO) reports 377 that the spike protein of coronavirus has shown more than 30 mutations in the new SARS-378

CoV-2 variant B.1.1.529 (Omicron). In order to investigate the effect of mutations on the 379 HLA-binding regions, we have used the reference spike protein of SARS-CoV-2 from NCBI. 380

Further, we identified the substituted mutations named as (A67V, We created the mutated spike protein sequence by substituting the new mutations in the 394 reference protein sequence. Then, we utilize the "SCAN" module (with peptide length = 9) of 395 HLA nc Pred server, for the identification of HLA-binding regions in the reference and altered 396 spike proteins. After that, we mapped the disparities in the reference and variant spike protein 397 sequences. We found that in alpha strain, a single substitution T716I in peptide 398 "NSIAIPINF", results in the gain of binding ability for HLA-G*01:01; similarly E484K 399 substitution in "KGFNCYFPL" peptide made it a binder for HLA-G*01:03, HLA-G*01:04, 400 and HLA-E*01:01. However, due to mutation L452R in peptide "KVGGNYNYR" results in 401 the loss of binding ability for HLA-G*01:03, and HLA-G*01:04 in delta strain. In case of 402 recent strain omicron (B.1.1.529), mutations has resulted into the changes in the binding 403 ability of various regions of spike proteins as shown in Table 5 . The complete results for the 404 binding prediction for alpha, beta, delta and omicron strains are provided in Supplementary 405 Table S3 , S4, S5, and S6, respectively. We hope that these findings can be used by scientific 406 community for further investigation and designing of potential immunotherapies/vaccines 407 against the new or future COVID-19 strains. 408 

The non-classical HLA such as, HLA-G acts as an immunomodulatory molecule and natural 415 guard while providing protection during fetus development [60, 61] , whereas, HLA-E 416 triggers immune responses via activating inflammatory cytokines during viral infections [9, 417 32, 62, 63] . Of note, the over-expression of HLA-G may induce the immune suppressive 418 microenvironment, which may help in evading tumor cells from our innate and adaptive Furthermore, various models were developed using N 8 , C 8 , N 8 C 8 , and AA 15 binary profiles for 442 each allele datasets. Our results indicate that, models developed on AA 15 binary profile-based 443 features achieve highest performance (i.e., AUC 0.99 and accuracy >95%) on training and 444 validation dataset for HLA-G*01:01 allele using SVC classifier. We have used the best 445 models for each non-classical HLA-binders and developed a web-server named 446 "HLA nc Pred" to predict and scan non-classical HLA-binding peptides. We also provide the 447 standalone package for the bulk scale non-classical HLA binder prediction. 448

Additionally, we utilized the SCAN module of our server for the prediction of HLA-449 binding/non-binding peptides in the spike protein of new strain of SARS-CoV-2 i.e., 450 B.1.1.529 (Omicron). We identified 431 promiscuous binders, where 80, 155, 56, 57, and 83 451 binders were predicted for HLA-E*01:01,-E*01:03, -G*01:01, -G*01:03, -G*01:04 allele, 452 respectively. From the prediction, we observed that due to the new mutations occurred in 453 B.1.1.529 (Omicron) variant, several peptide regions have shown the opposite binding trait in 454 comparison with the reference spike protein (Table 5 ). For instance, mutations Δ 211 and 455 L212I, changed the binding behaviour of "DLPQGFSAL" peptide for all non-classical HLA 456 alleles. These observations can benefit the scientific community for designing vaccine against 457 the deadly virus. In addition, researches can use this tool to predict the binding peptides of 458 non-classical HLA-alleles against different pathogenic, autoimmune and viral infections. We 459 anticipate that this method will benefit the community working in the area of vaccine and 460 HLA-based immunotherapy designing. The complete architecture of the HLA nc Pred is shown 461 in Figure 5 . 462 GPSR penned the manuscript. GPSR conceived and coordinated the project. All authors have 476 read and approved the final manuscript. 477

An introduction to immunology and 488 immunopathology

Overview of the immune response

The HLA system: genetics, immunology, clinical testing, and clinical 492 implications

The human major histocompatability complex: lessons from the 494 DNA sequence

CD8(+) T Lymphocyte and NK Cell Network: Circuitry 498 in the Cytotoxic Domain of Immunity

HLA and infectious diseases

Immune Response, and 502 Susceptibility to COVID-19

Do Classical and Non-Classical HLA Alleles Modulate Immune Response to Human 505

Immunodeficiency Virus and Hepatitis C Virus Infections?

Defective MHC class I antigen surface expression promotes 507 cellular survival through elevated ER stress and modulation of p53 function

Role of altered expression of HLA class I 510 molecules in cancer progression

HLA and melanoma: multiple alterations 512 in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank

The Pathophysiological Impact of HLA 515

Expression and Regulatory T Cells in Malignant Melanoma: A Review, 516

Immunomodulatory properties of HLA-G in infectious 518 diseases

Immunoregulatory Role of HLA-G in Allergic 520 Diseases

The immunotolerance role of HLA-G

Matrix metalloproteinase-2 (MMP-2) 524 generates soluble HLA-G1 by cell surface proteolytic shedding

Novel landscape of HLA-G isoforms 527 expressed in clear cell renal cell carcinoma patients

NKG2A/CD94 Is a New Immune Receptor for 529 HLA-G and Distinguishes Amino Acid Differences in the HLA-G Heavy Chain

The role of HLA-G in immunity and 532 hematopoiesis

A class I antigen, HLA-G, expressed in human 534 trophoblasts

Maternal/fetal interactions: the role of the MHC class I 536 molecule HLA-G

Application of human leukocyte antigen-G expression in the diagnosis of 538 human cancer

HLA-G and immune evasion in cancer cells

Biology of HLA-G in cancer: a candidate 542 molecule for therapeutic intervention?

HLA-G Molecules in Autoimmune Diseases 544 and Infections

Puzzling out the COVID-19: Therapy targeting HLA-G and HLA-E

The role of HLA-G in parasitic diseases

Non-classical MHC-I human leukocyte antigen 550 (HLA-G) in hepatotropic viral infections and in hepatocellular carcinoma

The Role of HLA-G Molecule and HLA-G 553

Gene Polymorphisms in Tumors, Viral Hepatitis, and Parasitic Diseases

HLA-E: a novel player for 556 histocompatibility

Characteristics of HLA-E Restricted T-Cell 558 Responses and Their Role in Infectious Diseases

Identification of HLA-E-specific alloreactive T 560 lymphocytes: a cell subset that undergoes preferential expansion in mixed lymphocyte culture 561 and displays a broad cytolytic activity against allogeneic cells

Human T cell receptor-mediated recognition 564 of HLA-E

Epstein-Barr virus peptide presented by 566 HLA-E is predominantly recognized by CD8(bright) cells in multiple sclerosis patients

HLA-E-restricted recognition of 569 cytomegalovirus-derived peptides by human CD8+ cytolytic T lymphocytes

Identification of effector-memory CMV-572 specific T lymphocytes that kill CMV-infected target cells in an HLA-E-restricted fashion

Crew MD, Cannon MJ, Phanavanh B et al. An HLA-E single chain trimer inhibits 577 human NK cell reactivity towards porcine cells

Harnessing HLA-E-restricted CD8 T 579 lymphocytes for adoptive cell therapy of patients with severe COVID-19

HLA-E is a major ligand for the natural killer 582 inhibitory receptor CD94/NKG2A

HLA-E Binding Peptide as a Potential Therapeutic 584 Candidate for High-Risk Multiple Myeloma

HLA-E inhibitor enhances the killing of neuroblastoma 586 stem cells by co-cultured dendritic cells and cytokine-induced killer cells loaded with 587 membrane-based microparticles

ProPred: prediction of HLA-DR binding sites

ProPred1: prediction of promiscuous MHC Class-I binding 591 sites

Predicting HLA class II antigen 593 presentation through integrated deep learning

NetMHCpan-4.0: Improved Peptide-MHC Class I 595

Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data

MHCflurry 2.0: Improved Pan-Allele 598 Prediction of MHC Class I-Presented Peptides by Incorporating Antigen Processing

MATHLA: a robust framework for HLA-peptide binding 601 prediction integrating bidirectional LSTM and multiple head attention mechanism

Bairoch A, Apweiler R. The SWISS-PROT protein sequence database and its 606 supplement TrEMBL in

Two Sample Logo: a graphical representation 608 of the differences between two sets of sequence alignments

Computer-aided prediction and design of IL-6 611 inducing peptides: IL-6 plays a crucial role in COVID-19

B3Pred: A Random-Forest-Based Method for 613 Predicting and Designing Blood-Brain Barrier Penetrating Peptides

An approach for identifying N-615 acetylglucosamine interacting residues of a protein from its primary sequence

Computing wide range of protein/peptide 618 features from their sequence and structure

Scikit-learn: Machine Learning in 620 Python

GPSRdocker: a Docker-based resource for 622 genomics, proteomics and systems biology

Features of HLA class I expression and its clinical relevance in SARS-624

CoV-2: What do we know so far?

Expression/Disease Association Studies: 626 Success, Hurdles, and Perspectives

Roles of HLA-G in the Maternal-Fetal Immune 628

Dimorphism of HLA-E and its Disease 630 Association

HLA-E: exploiting pathogen-host 632 interactions for vaccine development

HLA-G Expressing Immune Cells in Immune 634 Mediated Diseases

Recent Advances in Our Understanding of 636 HLA-G Biology: Lessons from a Wide Spectrum of Human Diseases

First immunotherapeutic CAR-T cells 639 against the immune checkpoint protein HLA-G

The current work has not received any specific grant from any funding agencies. 469

The authors declare no competing financial and non-financial interests. 471Authors' contributions 472 AD, SP and GPSR collected and processed the datasets. AD, SP and GPSR implemented the 473 algorithms and developed the prediction models. AD, SP and GPSR analysed the results. SP, 474 and AD created the back-end of the web server the front-end user interface. AD, SP, and 475